Get startedLog in
    Picture of ORYZON Genomics SA logo

    ORY — ORYZON Genomics SA News Story

    0.000.00%
    es flag iconLast trade - 00:00
    HealthcareSpeculativeSmall CapSucker Stock
    All News

    Brief: Oryzon Presents Updated Positive Clinical Data For Iadademstat In AML

    Picture of ORYZON Genomics SA logoORYZON Genomics SA
    11/06/2026 07:12
    BRIEF-Oryzon Presents Updated Positive Clinical Data For Iadademstat In AML
    June 11 (Reuters) - Oryzon Genomics SA ORY.MC:
    • PRESENTS UPDATED POSITIVE CLINICAL DATA FOR IADADEMSTAT IN AML AT EHA 2026
    • IN FIRST LINE, IADADEMSTAT, AZACITIDINE, VENETOCLAX COMBO CONTINUES TO SHOW FAVORABLE SAFETY PROFILE
    • IADADEMSTAT COMBO SHOWS 100% ORR, 89% CRC, 78% CR IN AML FIRST-LINE (ALICE-2)
    • TREATMENT WITH IADADEMSTAT-AZACITIDINE-VENETOCLAX TRIPLET ENABLED HIGH PROPORTION OF PATIENTS TO TRANSITION TO ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION, POTENTIALLY IMPROVING LONG-TERM SURVIVAL
    Source text
    Further company coverage: ORY.MC

     (Gdansk Newsroom)
     ((Gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))

    Recent news on ORYZON Genomics SA

    See all news